Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

21. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study 29412502 2018 03 12 1471-0528 2018 Feb 07 BJOG : an international journal of obstetrics and gynaecology BJOG The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study. 10.1111/1471-0528.15151 To obtain evidence of the effects of metformin and statins on the incidence of ovarian (...) cancer in women with type 2 diabetes (T2D). A retrospective cohort study and nested case-control study. The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers. A cohort of 137 643 women over 40 years old and diagnosed with T2D during 1996-2011 in Finland. In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral anti-diabetic medication or statins. In the

EvidenceUpdates2018

22. Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis

Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis 29595132 2018 11 15 2515-4478 23 2 2018 Apr BMJ evidence-based medicine BMJ Evid Based Med Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis. 64-69 10.1136/bmjebm-2017-110888 Synergistic effects of blood pressure-lowering drugs and statins are unknown, but are key to risk-based treatment decision strategies and fixed-combination polypills. We (...) conducted a systematic literature review and meta-analysis to test the hypothesis that the combined relative effects of blood pressure-lowering drugs and statins on cardiovascular outcomes are multiplicative. Two persons independently searched five data sources and hand-searched reference lists from earliest available to December 2017. We included factorial trials with at least two randomised interventions including one statin versus placebo factor and one blood pressure-lowering drug/more intense blood

BMJ evidence-based medicine2018 Full Text: Link to full Text with Trip Pro

23. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies 29463520 2018 03 01 1468-2060 2018 Feb 20 Annals of the rheumatic diseases Ann. Rheum. Dis. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. annrheumdis-2017-212461 10.1136/annrheumdis-2017-212461 Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase (...) inhibitors and other disease-modifying antirheumatic drugs. Lipid data were analysed from phase II and III studies of 4 mg (n=997) and 2 mg (n=479) oral baricitinib administered once daily in patients with moderate-to-severe active RA. Lipoprotein particle size and number and GlycA were evaluated with nuclear magnetic resonance in one phase III study. The effect of statin therapy on lipid levels was evaluated in patients on statins at baseline and in patients who initiated statins during the study

EvidenceUpdates2018

24. Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone?

Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone? Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics (...) Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone? View/ Open Date 2017-09 Format Metadata Abstract Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone? EVIDENCE-BASED ANSWER: Yes. Adding prescription-strength fish oil, or omega-3 fatty acids (OM3FA), to statin therapy is associated with an additional 20 percent to 30 percent reduction in triglyceride (TG

Evidence Based Practice 2018

25. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population.

Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. Background: Five major organizations recently published guidelines for using statins to prevent atherosclerotic cardiovascular disease (ASCVD): in 2013, the American College of Cardiology/American Heart Association (ACC/AHA); in 2014, the United Kingdom's National Institute for Health and Care Excellence (NICE); and in 2016, the Canadian Cardiovascular Society (CCS), the U.S (...) . Preventive Services Task Force (USPSTF), and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS). Objective: To compare the utility of these guidelines for primary prevention of ASCVD. Design: Observational study of actual ASCVD events during 10 years, followed by a modeling study to estimate the effectiveness of different guidelines. Setting: The Copenhagen General Population Study. Participants: 45 750 Danish persons aged 40 to 75 years who did not use statins and did not have

Annals of Internal Medicine2018

26. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) 28972004 2017 12 26 2017 12 26 1524-4539 136 25 2017 Dec 19 Circulation Circulation Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 2440-2450 10.1161 (...) /CIRCULATIONAHA.117.029095 Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial

EvidenceUpdates2018

27. Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack

Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack 29070714 2017 12 19 2017 12 19 1524-4628 48 12 2017 Dec Stroke Stroke Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. 3245-3251 10.1161/STROKEAHA.117.019141 Although there is no overall association between statin use and intracerebral hemorrhage (ICH), whether there is an increased risk among those (...) with a history of ischemic stroke (IS) or transient ischemic attack (TIA) remains controversial. We evaluated the relationship of preadmission statin use with the risk of ICH in patients with a history of IS or TIA in a population-based cohort. The Health Improvement Network primary care database in the United Kingdom was used to identify new users of low-dose aspirin and a matched comparison. Both cohorts were followed to identify incident cases of ICH, with validation by manual review of patient records

EvidenceUpdates2018

29. Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)

Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient) 29030478 2017 10 26 2017 10 26 1524-4628 48 11 2017 Nov Stroke Stroke Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). 3057-3063 10.1161/STROKEAHA.117.017623 Several studies suggested (...) that statins during hospitalization were associated with better disability outcomes in patients with acute ischemic stroke, but only 1 small randomized trial is available. We conducted a multicenter, open-label, randomized controlled trial in patients with acute ischemic strokes in 11 hospitals in Japan. Patients with acute ischemic stroke and dyslipidemia randomly received statins within 24 hours after admission in the early group or on the seventh day in the delayed group, in a 1:1 ratio. Statins were

EvidenceUpdates2017

30. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial ClinicalEfficacyandSafetyofEvolocumab inHigh-RiskPatientsReceivingaStatin SecondaryAnalysisofPatientsWithLowLDLCholesterol LevelsandinThoseAlreadyReceivingaMaximal-Potency StatininaRandomizedClinicalTrial RobertP.Giugliano,MD,SM;AnthonyKeech,MD;SabinaA.Murphy,MPH (...) , MA02115(rgiugliano@bwh.harvard .edu). Research JAMACardiology | BriefReport (Reprinted) 1385 © 2017 American Medical Association. All rights reserved. Downloaded From: on 12/07/2018S everalguidelinesendorseatargetlow-densitylipopro- teincholesterol(LDL-C)leveloflessthan70mg/dL(to converttomillimolesperliter,multiplyby0.0259)ora threshold for treatment of at least 70 mg/dL in the highest- risk patients for secondary prevention of cardiovascular events. 1-4 Likewise, high-intensity statin regimens (ie

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

31. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. BACKGROUND: Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated (...) in adolescents. METHODS: We screened 4407 adolescents with type 1 diabetes between the ages of 10 and 16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes. The primary outcome for both interventions was the change in albumin excretion

NEJM2017

32. Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study

Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study 28700275 2017 07 12 2017 09 15 2017 09 19 1527-7755 35 25 2017 Sep 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study. 2927-2933 10.1200/JCO.2016.71.3594 Purpose Cancer and cardiovascular disease share risk (...) factors, and there is some evidence that statins reduce cancer mortality. We sought to determine the accuracy of the 2013 American College of Cardiology/American Heart Association statin eligibility criteria to identify individuals at a higher risk of developing cancer or of dying as a result of cancer or other noncardiovascular causes. Methods We included 2,196 participants (50.5 ± 8.1 years of age; 55% female) who were statin naïve and free of cancer at baseline from the offspring and third

EvidenceUpdates2017

33. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)

Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial) 28781026 2017 08 07 2017 09 01 2017 09 01 1879-1913 120 6 2017 Sep 15 The American journal of cardiology Am. J. Cardiol. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary (...) Intervention (ADHERENCE Trial). 893-897 S0002-9149(17)31023-8 10.1016/j.amjcard.2017.06.015 Low-density lipoprotein cholesterol (LDL-C) reduction is associated with a significant decrease in mortality, and statins represent the most effective drugs to achieve this. However, side effects of statins are very common and may lead to treatment discontinuation. Nutraceuticals are a combination of natural components that have shown efficacy in lowering LDL-C concentration when used alone or in association

EvidenceUpdates2017

34. Statins in secondary cardiovascular prevention

Statins in secondary cardiovascular prevention Prescrire IN ENGLISH - Spotlight ''Statins in secondary cardiovascular prevention'', 1 September 2017 {1} {1} {1} | | > > > Statins in secondary cardiovascular prevention Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in secondary cardiovascular prevention FEATURED REVIEW What is the evidence (...) for the efficacy of statins in secondary cardiovascular prevention? In which situations are they effective? What are their harms? To answer these questions, we reviewed the available evidence using the standard Prescrire methodology. Free abstract available here; full review (8 pages) available for download by subscribers. Abstract For patients who have already had a cardiovascular event or who have stable angina or peripheral artery disease, the prevention of cardiovascular events ("secondary prevention

Prescrire2017

35. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. Importance: Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered. Objective: To estimate the association between changes in levels of LDL-C (and other lipoproteins) and the risk (...) in apoB level (OR, 0.782 [95% CI, 0.720-0.845] vs 0.793 [95% CI, 0.774-0.812]; P = .79 for difference), but a significantly attenuated risk of CHD per unit change in LDL-C level (OR, 0.916 [95% CI, 0.890-0.943] vs 0.831 [95% CI, 0.816-0.847]; P < .001) compared with a genetic score associated with concordant changes in levels of LDL-C and apoB. Conclusions and Relevance: Combined exposure to variants in the genes that encode the targets of CETP inhibitors and statins was associated with discordant

JAMA2017

36. What are the indications for treatment of hypercholesterolemia with statin therapy in obese children?

What are the indications for treatment of hypercholesterolemia with statin therapy in obese children? What are the indications for treatment of hypercholesterolemia with statin therapy in obese children? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What are the indications for treatment of hypercholesterolemia with (...) statin therapy in obese children? View/ Open Date 2017-06 Format Metadata Abstract What are the indications for treatment of hypercholesterolemia with statin therapy in obese children? Evidence-based answer: After 6 months of dietary and lifestyle modifications, statin therapy should be considered for children 11 to 21 years old with a BMI [greater than or equal to] 97th percentile and LDL-C [greater than or equal to]160 mg/dL or if LDL-C is between 130 and 160 mg/dL and other risk factors

Evidence Based Practice 2017

37. Should adult patients undergoing cardiac surgery receive preoperative statin therapy?

Should adult patients undergoing cardiac surgery receive preoperative statin therapy? Should adult patients undergoing cardiac surgery receive preoperative statin therapy? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Should adult patients undergoing cardiac surgery receive preoperative statin therapy? View/ Open (...) Date 2017-06 Format Metadata Abstract Should adult patients undergoing cardiac surgery receive preoperative statin therapy? Evidence-based answer: In adult patients undergoing coronary artery bypass grafting (CABG), preoperative statin therapy reduces the incidence of postoperative atrial fibrillation (AF) by 50% and length of hospital stay by about a half day, but does not reduce short-term mortality. No benefit is seen with preoperative statin therapy for isolated valvular surgery in the absence

Evidence Based Practice 2017

38. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study

Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study 28684558 2017 07 07 2017 07 07 1468-2060 2017 Jul 06 Annals of the rheumatic diseases Ann. Rheum. Dis. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. annrheumdis-2016-210936 10.1136/annrheumdis-2016-210936 To examine the association between the use of statins and the risk of systemic lupus erythematosus (SLE) with focus on describing (...) the patterns of risks over time. A population-based cohort study using the UK Clinical Practice Research Datalink. All patients aged 40 years or older who had at least one prescription of statins during the period 1995-2009 were selected and matched by age, sex, practice and date of first prescription to non-users. The follow-up period of statin users was divided into periods of current, recent and past exposure, with patients moving among these three exposure categories over time. Current statin users

EvidenceUpdates2017

40. Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study.

Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study. Background: Many patients discontinue statin treatment, often after having a possible adverse reaction. The risks and benefits of continued statin therapy after an adverse reaction are not known. Objective: To examine the relationship between continuation of statin therapy (any prescription within 12 months after an adverse reaction) and clinical outcomes. Design: Retrospective cohort study. Setting (...) : Primary care practices affiliated with 2 academic medical centers. Participants: Patients with a presumed adverse reaction to a statin between 2000 and 2011. Measurements: Information on adverse reactions to statins was obtained from structured electronic medical record data or natural-language processing of narrative provider notes. The primary composite outcome was time to a cardiovascular event (myocardial infarction or stroke) or death. Results: Most (81%) of the adverse reactions to statins were

Annals of Internal Medicine2017